Symbols / GTBP
GTBP Chart
About
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. It develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 that targets B7-H3 on the surface of advanced solid tumors; and GTB-7550, a product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 12.44M |
| Enterprise Value | 2.26M | Income | -9.33M | Sales | — |
| Book/sh | 0.50 | Cash/sh | 0.24 | Dividend Yield | — |
| Payout | 0.00% | Employees | 1 | IPO | — |
| P/E | — | Forward P/E | -0.04 | PEG | — |
| P/S | — | P/B | 0.94 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 1.91 |
| Current Ratio | 3.27 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -3.50 | EPS next Y | -10.80 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-14 16:00 | ROA | -119.47% |
| ROE | -3.57% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 26.65M |
| Shs Float | 10.30M | Short Float | 10.11% | Short Ratio | 1.77 |
| Short Interest | — | 52W High | 3.85 | 52W Low | 0.40 |
| Beta | 1.25 | Avg Volume | 1.61M | Volume | 521.57K |
| Target Price | $8.00 | Recom | None | Prev Close | $0.45 |
| Price | $0.47 | Change | 3.69% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.00
Mean price target
2. Current target
$0.47
Latest analyst target
3. DCF / Fair value
$-7.44
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.47
Low
$8.00
High
$8.00
Mean
$8.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-12-02 | init | Roth MKM | — → Buy | $11 |
- GT Biopharma (NASDAQ: GTBP) posts $3.1M net loss as GTB-3650 Phase 1 trial enrollment continues - Stock Titan Fri, 14 Nov 2025 08
- GT Biopharma stock rises as Phase 1 trial advances to higher dose - Investing.com Wed, 19 Nov 2025 08
- EXCLUSIVE: GT Biopharma Reports Progresses Phase 1 Trial Of Lead Drug Candidate For Blood Cancers - Yahoo Finance Wed, 08 Oct 2025 07
- GT Biopharma Stock Logs Best Session In Over 9 Months On Promising Cancer Trial Data; Retail Eyes Double-Digit Rally - Stocktwits Wed, 08 Oct 2025 07
- GT Biopharma Reports Successful Phase 1 Trial Progress for GTB-3650 in Hematologic Malignancies - Quiver Quantitative Wed, 08 Oct 2025 07
- GT Biopharma Alters Preferred Stockholder Rights - TipRanks Fri, 26 Sep 2025 07
- GT Biopharma Initiates Cohort 3 Dosing; No DLTs, Cohort 4 Planned | GTBP Stock News - Stock Titan Wed, 08 Oct 2025 07
- How GTBP stock reacts to oil prices - Earnings Recap Report & Technical Buy Zone Confirmations - mfd.ru Wed, 11 Feb 2026 09
- Trade Recap: Can GTBP stock outperform in a bear market - New Guidance & Stock Portfolio Risk Control - baoquankhu1.vn Sun, 15 Feb 2026 11
- Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape - PR Newswire Fri, 16 Jan 2026 08
- Stocks & Markets Podcast: Biotech CEO reveals the science of humane cancer treatment - thestreet.com Mon, 08 Dec 2025 08
- GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing - Intellectia AI Fri, 19 Dec 2025 08
- Should I invest in GTBP before earnings - Earnings Trend Report & Smart Money Movement Tracker - mfd.ru Fri, 20 Feb 2026 18
- GT Biopharma Strengthens Board with Biotech Exit Expert Andrew Ritter: 3 Successful Company Sales - Stock Titan hu, 15 May 2025 07
- Here's Why GT Biopharma, Inc. (GTBP) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance Fri, 02 Jun 2023 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -13.96M | -12.78M | -20.96M | -57.48M |
| TotalUnusualItems | 800.00K | 5.39M | 89.00K | 182.00K |
| TotalUnusualItemsExcludingGoodwill | 800.00K | 5.39M | 89.00K | 182.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -13.16M | -7.60M | -20.88M | -58.01M |
| EBITDA | -13.16M | -7.38M | -20.88M | -57.30M |
| EBIT | -13.16M | -7.38M | -20.88M | -57.30M |
| NetInterestIncome | 402.00K | 567.00K | 284.00K | -680.00K |
| InterestExpense | 0.00 | 213.00K | 8.00K | 718.00K |
| InterestIncome | 402.00K | 780.00K | 292.00K | 38.00K |
| NormalizedIncome | -13.96M | -12.99M | -20.97M | -58.20M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -13.16M | -7.60M | -20.88M | -58.01M |
| TotalExpenses | 14.36M | 13.58M | 21.26M | 57.52M |
| TotalOperatingIncomeAsReported | -14.36M | -13.58M | -21.26M | -57.52M |
| DilutedAverageShares | 1.90M | 1.35M | 1.07M | 938.52K |
| BasicAverageShares | 1.90M | 1.35M | 1.07M | 938.52K |
| DilutedEPS | -6.94 | -5.64 | -19.46 | -61.80 |
| BasicEPS | -6.94 | -5.64 | -19.46 | -61.80 |
| DilutedNIAvailtoComStockholders | -13.16M | -7.60M | -20.88M | -58.01M |
| NetIncomeCommonStockholders | -13.16M | -7.60M | -20.88M | -58.01M |
| NetIncome | -13.16M | -7.60M | -20.88M | -58.01M |
| NetIncomeIncludingNoncontrollingInterests | -13.16M | -7.60M | -20.88M | -58.01M |
| NetIncomeContinuousOperations | -13.16M | -7.60M | -20.88M | -58.01M |
| PretaxIncome | -13.16M | -7.60M | -20.88M | -58.01M |
| OtherIncomeExpense | 800.00K | 5.41M | 89.00K | 182.00K |
| OtherNonOperatingIncomeExpenses | 20.00K | |||
| SpecialIncomeCharges | 0.00 | 547.00K | 0.00 | 0.00 |
| OtherSpecialCharges | -547.00K | |||
| GainOnSaleOfSecurity | 800.00K | 4.84M | 89.00K | 182.00K |
| NetNonOperatingInterestIncomeExpense | 402.00K | 567.00K | 284.00K | -680.00K |
| InterestExpenseNonOperating | 0.00 | 213.00K | 8.00K | 718.00K |
| InterestIncomeNonOperating | 402.00K | 780.00K | 292.00K | 38.00K |
| OperatingIncome | -14.36M | -13.58M | -21.26M | -57.52M |
| OperatingExpense | 14.36M | 13.58M | 21.26M | 57.52M |
| ResearchAndDevelopment | 5.80M | 6.47M | 8.81M | 9.59M |
| SellingGeneralAndAdministration | 8.57M | 7.11M | 12.45M | 47.92M |
| GeneralAndAdministrativeExpense | 47.92M | |||
| OtherGandA | 47.92M | |||
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| PreferredSharesNumber | 121.23K | 121.23K | 121.23K | 121.23K |
| OrdinarySharesNumber | 2.23M | 1.38M | 1.09M | 1.07M |
| ShareIssued | 2.23M | 1.38M | 1.09M | 1.07M |
| TotalDebt | 0.00 | 58.00K | 174.00K | 31.00K |
| TangibleBookValue | -1.67M | 7.47M | 11.73M | 21.91M |
| InvestedCapital | -1.67M | 7.47M | 11.73M | 21.94M |
| WorkingCapital | -1.67M | 7.42M | 11.62M | 21.91M |
| NetTangibleAssets | -1.67M | 7.48M | 11.73M | 21.91M |
| CapitalLeaseObligations | 0.00 | 58.00K | 174.00K | 0.00 |
| CommonStockEquity | -1.67M | 7.47M | 11.73M | 21.91M |
| PreferredStockEquity | 1.00K | 1.00K | 1.00K | 1.00K |
| TotalCapitalization | -1.67M | 7.48M | 11.73M | 21.91M |
| TotalEquityGrossMinorityInterest | -1.67M | 7.48M | 11.73M | 21.91M |
| StockholdersEquity | -1.67M | 7.48M | 11.73M | 21.91M |
| RetainedEarnings | -695.23M | -682.07M | -674.47M | -653.58M |
| AdditionalPaidInCapital | 693.55M | 689.54M | 686.17M | 674.35M |
| CapitalStock | 3.00K | 2.00K | 34.00K | 1.15M |
| CommonStock | 2.00K | 1.00K | 33.00K | 1.15M |
| PreferredStock | 1.00K | 1.00K | 1.00K | 1.00K |
| TotalLiabilitiesNetMinorityInterest | 5.90M | 6.63M | 5.00M | 10.26M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 64.00K | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 64.00K | 0.00 | |
| LongTermCapitalLeaseObligation | 0.00 | 64.00K | 0.00 | |
| CurrentLiabilities | 5.90M | 6.63M | 4.94M | 10.26M |
| OtherCurrentLiabilities | 252.00K | 1.05M | 19.00K | 138.00K |
| CurrentDebtAndCapitalLeaseObligation | 58.00K | 110.00K | 31.00K | |
| CurrentCapitalLeaseObligation | 0.00 | 58.00K | 110.00K | 0.00 |
| CurrentDebt | 31.00K | |||
| LineOfCredit | 0.00 | 31.00K | ||
| PayablesAndAccruedExpenses | 5.65M | 5.52M | 4.81M | 10.09M |
| CurrentAccruedExpenses | 1.80M | 1.20M | 1.67M | 1.90M |
| InterestPayable | 0.00 | |||
| Payables | 3.85M | 4.33M | 3.14M | 8.19M |
| AccountsPayable | 3.85M | 4.33M | 3.14M | 8.19M |
| TotalAssets | 4.23M | 14.11M | 16.74M | 32.17M |
| TotalNonCurrentAssets | 0.00 | 53.00K | 174.00K | 0.00 |
| NonCurrentPrepaidAssets | 0.00 | 9.00K | 0.00 | |
| NetPPE | 0.00 | 53.00K | 165.00K | 0.00 |
| GrossPPE | 0.00 | 53.00K | 165.00K | 0.00 |
| OtherProperties | 53.00K | 165.00K | ||
| CurrentAssets | 4.23M | 14.06M | 16.56M | 32.17M |
| OtherCurrentAssets | 188.00K | 84.00K | 54.00K | 190.00K |
| RestrictedCash | 93.00K | 0.00 | ||
| PrepaidAssets | 190.00K | |||
| CashCashEquivalentsAndShortTermInvestments | 3.95M | 13.97M | 16.51M | 31.98M |
| OtherShortTermInvestments | 0.00 | 12.89M | 10.84M | 23.01M |
| CashAndCashEquivalents | 3.95M | 1.08M | 5.67M | 8.97M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -12.90M | -8.85M | -15.22M | -15.61M |
| RepurchaseOfCapitalStock | 0.00 | -224.00K | 0.00 | |
| IssuanceOfDebt | 0.00 | 1.21M | ||
| IssuanceOfCapitalStock | 2.98M | 6.27M | 0.00 | 24.68M |
| InterestPaidSupplementalData | 0.00 | 213.00K | 0.00 | 0.00 |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 4.04M | 1.08M | 5.67M | 8.97M |
| BeginningCashPosition | 1.08M | 5.67M | 8.97M | 5.30M |
| ChangesInCash | 2.96M | -4.59M | -3.30M | 3.67M |
| FinancingCashFlow | 2.98M | 6.27M | -224.00K | 42.32M |
| CashFlowFromContinuingFinancingActivities | 2.98M | 6.27M | -224.00K | 42.32M |
| ProceedsFromStockOptionExercised | 0.00 | 16.43M | ||
| NetCommonStockIssuance | 2.98M | 6.27M | -224.00K | 24.68M |
| CommonStockPayments | 0.00 | -224.00K | 0.00 | |
| CommonStockIssuance | 2.98M | 6.27M | 0.00 | 24.68M |
| NetIssuancePaymentsOfDebt | 0.00 | 1.21M | ||
| NetLongTermDebtIssuance | 0.00 | 1.21M | ||
| LongTermDebtIssuance | 0.00 | 1.21M | ||
| InvestingCashFlow | 12.89M | -2.01M | 12.14M | -23.04M |
| CashFlowFromContinuingInvestingActivities | 12.89M | -2.01M | 12.14M | -23.04M |
| NetInvestmentPurchaseAndSale | 12.89M | -2.01M | 12.14M | -23.04M |
| PurchaseOfInvestment | -23.04M | |||
| OperatingCashFlow | -12.90M | -8.85M | -15.22M | -15.61M |
| CashFlowFromContinuingOperatingActivities | -12.90M | -8.85M | -15.22M | -15.61M |
| ChangeInWorkingCapital | 828.00K | 1.94M | -1.99M | 7.94M |
| ChangeInOtherCurrentLiabilities | -58.00K | -116.00K | -86.00K | 0.00 |
| ChangeInOtherCurrentAssets | 53.00K | 112.00K | 95.00K | 0.00 |
| ChangeInPayablesAndAccruedExpense | 937.00K | 1.96M | -2.03M | 7.77M |
| ChangeInAccruedExpense | 0.00 | 689.00K | ||
| ChangeInInterestPayable | 0.00 | 689.00K | ||
| ChangeInPayable | -2.03M | 7.08M | ||
| ChangeInAccountPayable | -2.03M | 7.08M | ||
| ChangeInPrepaidAssets | -104.00K | -21.00K | 127.00K | 174.00K |
| OtherNonCashItems | 112.00K | 130.00K | 720.00K | |
| StockBasedCompensation | 230.00K | 2.20M | 7.65M | 33.93M |
| UnrealizedGainLossOnInvestmentSecurities | 0.00 | -48.00K | 30.00K | 29.00K |
| OperatingGainsLosses | -800.00K | -5.34M | -150.00K | -211.00K |
| GainLossOnInvestmentSecurities | -800.00K | -4.80M | -119.00K | -211.00K |
| GainLossOnSaleOfPPE | 112.00K | 95.00K | ||
| NetIncomeFromContinuingOperations | -13.16M | -7.60M | -20.88M | -58.01M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for GTBP
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|